Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4084 USD | +1.34% |
|
-1.85% | -38.49% |
Business Summary
Number of employees: 67
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapeutics
100.0
%
| 14 | 100.0 % | 16 | 100.0 % | +11.66% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Lawrence Blatt
CEO | Chief Executive Officer | 62 | 18-02-04 |
Lesley Calhoun
DFI | Director of Finance/CFO | 58 | 20-05-31 |
Julian Symons
CTO | Chief Tech/Sci/R&D Officer | 63 | 18-04-30 |
Jordyn Tarazi
IRC | Investor Relations Contact | - | 02-12 |
Human Resources Officer | - | - | |
Corporate Officer/Principal | 58 | 18-07-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Lawrence Blatt
CEO | Chief Executive Officer | 62 | 18-02-04 |
Director/Board Member | 62 | 18-07-31 | |
K. Hirth
BRD | Director/Board Member | 72 | 18-07-31 |
Jim Scopa
BRD | Director/Board Member | 65 | 21-04-26 |
Bridget Martell
BRD | Director/Board Member | 58 | 21-11-15 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 3,092,338 | 0 | 0 | 76.28 % |
Stock B | 1 | 75,017,589 | 59,584,137 ( 79.43 %) | 0 |
Company contact information
Aligos Therapeutics, Inc.
1 Corporate Drive 2nd floor
94080, South San Francisco
+800 466 6059
http://www.aligos.com![address Aligos Therapeutics, Inc.(ALGS)](https://cdn.zonebourse.com/static/address/113013160.png)
Sector
Sales per region
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.49% | 31.48M | |
+25.80% | 52.73B | |
+37.49% | 39B | |
-9.09% | 38.52B | |
+27.76% | 30.38B | |
-12.26% | 26.39B | |
+10.47% | 26.08B | |
+45.00% | 14.15B | |
+32.34% | 12.6B | |
-6.12% | 11.51B |
- Stock Market
- Equities
- ALGS Stock
- Company Aligos Therapeutics, Inc.